Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088809980> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2088809980 endingPage "224" @default.
- W2088809980 startingPage "219" @default.
- W2088809980 abstract "Le clonazépam est une 1-4 benzodiazépine dont l’indication principale est le traitement de l’épilepsie et de l’état de mal convulsif. Rapidement résorbé par voie orale, il est largement distribué dans l’organisme et transformé en plusieurs métabolites, peu ou non actifs, retrouvés dans les urines (70 %) et les selles. Sa demi-vie terminale est longue, de l’ordre de 40 h. Chez l’adulte et l’enfant, plusieurs études ont montré une relation concentration–effet. Cependant, il existe une grande variabilité inter-individuelle dans la relation dose-concentration. Des concentrations sanguines à atteindre, comprises entre 15 et 50 μg/L, semblent pouvoir être retenues pour contrôler la majorité des crises convulsives. Le suivi thérapeutique pharmacologique (STP) du clonazépam peut être considéré comme éventuellement utile en cas d’association avec des médicaments inducteurs ou inhibiteurs des CYP450, de suspicion de non-observance ou de signes de toxicité. Clonazepam is a 1-4 benzodiazepine mainly used to treat epilepsy and epileptiform convulsion state. Rapidly absorbed after oral administration, it is widely distributed in the organism and is extensively converted in metabolites, poorly or not active, eliminated mainly in urine (70%) and feces. Elimination half-life is long, around 40 h. In adult and child, several studies showed a concentration-effect relation. Meanwhile, a large inter-individual variability in the dose-concentration relation was observed. A 15-50 μg/L range of clonazepam blood concentrations appears to be retained as an acceptable target to control a majority of epileptic seizures. The Therapeutic Drug Monitoring (TDM) of clonazepam can be considered as possibly useful in case of association with CYP450 inducers or inhibitors, suspicion of poor observance, or toxicity signs." @default.
- W2088809980 created "2016-06-24" @default.
- W2088809980 creator A5014281848 @default.
- W2088809980 creator A5016920106 @default.
- W2088809980 creator A5072677255 @default.
- W2088809980 creator A5079765857 @default.
- W2088809980 creator A5084716432 @default.
- W2088809980 date "2010-05-01" @default.
- W2088809980 modified "2023-10-04" @default.
- W2088809980 title "Suivi thérapeutique pharmacologique du clonazépam" @default.
- W2088809980 cites W1522521679 @default.
- W2088809980 cites W1965275330 @default.
- W2088809980 cites W1971556333 @default.
- W2088809980 cites W1987657867 @default.
- W2088809980 cites W1991884352 @default.
- W2088809980 cites W2001784881 @default.
- W2088809980 cites W2008227560 @default.
- W2088809980 cites W2010462951 @default.
- W2088809980 cites W2015676818 @default.
- W2088809980 cites W2017706795 @default.
- W2088809980 cites W2022389996 @default.
- W2088809980 cites W2033336706 @default.
- W2088809980 cites W2037782568 @default.
- W2088809980 cites W2045975613 @default.
- W2088809980 cites W2047978949 @default.
- W2088809980 cites W2054087210 @default.
- W2088809980 cites W2059411645 @default.
- W2088809980 cites W2075489088 @default.
- W2088809980 cites W2079248878 @default.
- W2088809980 cites W2082158892 @default.
- W2088809980 cites W2087153802 @default.
- W2088809980 cites W2090571781 @default.
- W2088809980 cites W2130526286 @default.
- W2088809980 cites W2139391547 @default.
- W2088809980 cites W2164696797 @default.
- W2088809980 cites W2325185783 @default.
- W2088809980 cites W4242505263 @default.
- W2088809980 doi "https://doi.org/10.2515/therapie/2010027" @default.
- W2088809980 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20699074" @default.
- W2088809980 hasPublicationYear "2010" @default.
- W2088809980 type Work @default.
- W2088809980 sameAs 2088809980 @default.
- W2088809980 citedByCount "6" @default.
- W2088809980 countsByYear W20888099802014 @default.
- W2088809980 countsByYear W20888099802015 @default.
- W2088809980 countsByYear W20888099802016 @default.
- W2088809980 countsByYear W20888099802017 @default.
- W2088809980 countsByYear W20888099802018 @default.
- W2088809980 countsByYear W20888099802022 @default.
- W2088809980 crossrefType "journal-article" @default.
- W2088809980 hasAuthorship W2088809980A5014281848 @default.
- W2088809980 hasAuthorship W2088809980A5016920106 @default.
- W2088809980 hasAuthorship W2088809980A5072677255 @default.
- W2088809980 hasAuthorship W2088809980A5079765857 @default.
- W2088809980 hasAuthorship W2088809980A5084716432 @default.
- W2088809980 hasConcept C185592680 @default.
- W2088809980 hasConcept C2779426884 @default.
- W2088809980 hasConcept C71924100 @default.
- W2088809980 hasConcept C98274493 @default.
- W2088809980 hasConceptScore W2088809980C185592680 @default.
- W2088809980 hasConceptScore W2088809980C2779426884 @default.
- W2088809980 hasConceptScore W2088809980C71924100 @default.
- W2088809980 hasConceptScore W2088809980C98274493 @default.
- W2088809980 hasIssue "3" @default.
- W2088809980 hasLocation W20888099801 @default.
- W2088809980 hasLocation W20888099802 @default.
- W2088809980 hasOpenAccess W2088809980 @default.
- W2088809980 hasPrimaryLocation W20888099801 @default.
- W2088809980 hasRelatedWork W193686221 @default.
- W2088809980 hasRelatedWork W2074969755 @default.
- W2088809980 hasRelatedWork W2088667349 @default.
- W2088809980 hasRelatedWork W2092910380 @default.
- W2088809980 hasRelatedWork W2120557693 @default.
- W2088809980 hasRelatedWork W2412434707 @default.
- W2088809980 hasRelatedWork W2417065207 @default.
- W2088809980 hasRelatedWork W2553409270 @default.
- W2088809980 hasRelatedWork W1508436939 @default.
- W2088809980 hasRelatedWork W4290310807 @default.
- W2088809980 hasVolume "65" @default.
- W2088809980 isParatext "false" @default.
- W2088809980 isRetracted "false" @default.
- W2088809980 magId "2088809980" @default.
- W2088809980 workType "article" @default.